Sir,

The recent letter by Kulkarni *et al*.\[[@ref1]\] outlining the jet insufflation *jugaad* that was derived from a Jackson-Rees circuit, a 4 mm ID endotracheal tube connector, and Luer-lock venous extension tubing, offers a potentially viable alternative to commercially available jet ventilation devices such as the Enk Oxygen Flow Modulator (Cook Inc., Bloomington, IN, USA), the Rapid O~2~™ Insufflator (Meditech Systems Ltd, Shaftesbury, UK) and the Manujet III™ (VBM, Medizintechnik GmBH, Sula and Neckar, Germany) for use in cannot intubate--cannot ventilate situations in paediatric patients. Indeed, the authors\' improvised insufflator solution that offers both jet inspiration and active expiration exploits the Hagen--Poiseuille law in a very similar fashion to another relatively new commercially available device, the Ventrain^®^ (Ventinova Medical B. V., Eindhoven, Netherlands).\[[@ref2]\] This device has similarly been shown to allow both inspiration and active expiration when used with both short and long small-bore airway cannulae.\[[@ref3]\] The Ventrain device is a portable, easy to use, light weight, stand-alone high-pressure injector that uses up to 15 L/min in oxygen flow. Importantly, it has also withstood the evaluative rigor of medical equipment regulatory agencies making it potentially safer than the improvised device suggested by Kulkarni *et al*. That said, I congratulate these authors on their improvisation and ingenuity, as they appear to have independently validated and partially replicated the work that had been accomplished with the Ventrain.
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